REGENERON ONCOLOGY Trademark

Trademark Overview

On Wednesday, January 11, 2023, a trademark application was filed for REGENERON ONCOLOGY with the United States Patent and Trademark Office. The USPTO has given the REGENERON ONCOLOGY trademark a serial number of 97749337. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Monday, February 3, 2025. This trademark is owned by Regeneron Pharmaceuticals, Inc.. The REGENERON ONCOLOGY trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

Providing information in the field of cancer research and treatment
regeneron oncology

General Information

Serial Number97749337
Word MarkREGENERON ONCOLOGY
Filing DateWednesday, January 11, 2023
Status732 - THIRD EXTENSION - GRANTED
Status DateMonday, February 3, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 11, 2023

Trademark Statements

Goods and ServicesProviding information in the field of cancer research and treatment
NOT AVAILABLE"ONCOLOGY"

Classification Information

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, February 1, 2023
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameRegeneron Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTarrytown, NY 10591
Party NameRegeneron Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTarrytown, NY 10591

Trademark Events

Event DateEvent Description
Wednesday, March 8, 2023EXAMINERS AMENDMENT E-MAILED
Saturday, January 14, 2023NEW APPLICATION ENTERED
Wednesday, February 1, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 6, 2023ASSIGNED TO EXAMINER
Wednesday, March 8, 2023EXAMINERS AMENDMENT -WRITTEN
Wednesday, March 8, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, March 8, 2023EXAMINER'S AMENDMENT ENTERED
Wednesday, March 8, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 22, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 11, 2023PUBLISHED FOR OPPOSITION
Tuesday, April 11, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 6, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 14, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, May 14, 2024SOU EXTENSION 2 FILED
Tuesday, May 14, 2024SOU EXTENSION 2 GRANTED
Saturday, November 18, 2023SOU TEAS EXTENSION RECEIVED
Saturday, November 18, 2023SOU EXTENSION 1 FILED
Saturday, November 18, 2023SOU EXTENSION 1 GRANTED
Tuesday, November 21, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, November 16, 2024SOU EXTENSION 3 FILED
Saturday, November 16, 2024SOU TEAS EXTENSION RECEIVED
Friday, January 31, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, February 3, 2025SOU EXTENSION 3 GRANTED
Monday, February 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

oncology regeneron research treatment cancer field information providing